September 07, 2016
Moderna Enters New Growth Phase with Closing of $474 Million Equity Financing and its First BARDA Grant for up to $125 Million for Zika mRNA Vaccine
September 07, 2016
Moderna Announces Funding Award from BARDA for $8 Million with Potential of up to $125 Million to Accelerate Development of Zika Messenger RNA (mRNA) Vaccine
July 26, 2016
Moderna Therapeutics Provides Mid-Year Corporate Update, Announces Continued Clinical Development Progress and Pipeline Acceleration
July 26, 2016
AstraZeneca and Moderna Announce Filing of First Clinical Trial Application in Messenger RNA Therapeutics™ Collaboration
July 06, 2016
Vertex and Moderna Establish Exclusive Collaboration to Discover and Develop mRNA Therapeutics™ for Cystic Fibrosis
June 29, 2016
Merck and Moderna Announce Strategic Collaboration to Advance Novel mRNA-Based Personalized Cancer Vaccines with KEYTRUDA® (pembrolizumab) for the Treatment of Multiple Types of Cancer
June 06, 2016
Moderna Therapeutics and Charles River Laboratories Announce Strategic Collaboration to Scale Moderna’s Nonclinical Development Efforts for Novel mRNA Therapeutics
April 04, 2016
Moderna Announces Appointment of Dr. Michael Watson as President of Valera
March 28, 2016
Moderna Therapeutics Appoints Saqib Islam as Chief Business Officer
January 12, 2016
Moderna Therapeutics, Through Valera, its Infectious Disease Venture, Announces Initial Grant of up to $20 Million to Advance mRNA-Based Antibody Combination to Help Prevent HIV Infection

Pages